Boundless Bio
BOLD | NASDAQ
$2.41
-$0.09 (-3.60%)
At close: Nov 16, 2026, 4:00 PM ET
$2.39
-$0.02 (-0.83%)
After-hours:
Nov 16, 2026, 6:23 PM ET
Boundless Bio Company Profile
Company profile explainedCompany Profile
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
Key Executives
| Name | Position |
|---|---|
| Jessica Oien | President, Principal Executive Officer, Chief Legal Officer & Corporate Secretary |
| David Hinkle | Senior Vice President of Finance, Controller & Corporate Treasurer |
| Meredith Wesley | Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 4 | Filing |
| Oct 26, 2026 | 425 | Filing |
| Oct 26, 2026 | 4 | Filing |
| Oct 26, 2026 | 425 | Filing |
| Oct 20, 2026 | 4 | Filing |
| Oct 08, 2026 | S-4 | Filing |
| Aug 28, 2026 | 425 | Filing |
| Aug 28, 2026 | 8-K | Current Report |
| Aug 28, 2026 | 4 | Filing |
| Aug 27, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
Boundless Bio
| Country | United States |
| IPO Date | Mar 28, 2024 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Zachary Hornby |
Contact Details
10955 Alexandria Way San Diego,
California 92121 United States
Stock Details
| Ticker Symbol | BOLD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001782303 |
| CUSIP Number | 10170A100 |
| ISIN Number | US10170A1007 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove BOLD